New class action for Vistagen Therapeutics urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 3/16/2026

image for news Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Quantum Biopharma Ltd urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026.

image for news Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Gauzy Ltd. (GAUZ) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/6/2026.

image for news Bronstein, Gewirtz & Grossman, LLCUrgesGauzy, Ltd.Investorsto Act: Class Action Filed Alleging Investor Harm

One analyst estimates Tesla could ultimately make $25 billion a year by selling Optimus robots manufactured on former Model S and Model X production lines.

image for news Why Elon Musk is making a smart move by killing off Tesla's Model S and Model X

Ameriprise Financial Shows Rate Fears Are Overblown — Neutral

AMP   Seeking Alpha — January 29, 2026

Ameriprise Financial is reiterated as a 'Buy,' with shares offering over 10% additional upside and attractive value at 11.8x 2026 earnings. AMP's Q4 results showed 16% earnings growth, an 11% AUM increase to $1.7 trillion, and robust advisory fee growth, offsetting net investment income declines. Wealth management and asset management segments deliver strong organic growth and operating leverage, with recurring fees providing a stable revenue base.

image for news Ameriprise Financial Shows Rate Fears Are Overblown

Jacobs Increases Quarterly Dividend — Neutral

J   PRNewsWire — January 29, 2026

DALLAS, Jan. 29, 2026 /PRNewswire/ -- The Board of Directors of Jacobs (NYSE:J) has declared a quarterly cash dividend payable to shareholders in the amount of $0.36 per share of Jacobs common stock, an increase of 12.5% from its previous quarterly dividend of $0.32. This dividend will be paid on March 20, 2026, to shareholders of record as of the close of business on Feb. 20, 2026.

image for news Jacobs Increases Quarterly Dividend

Air India Orders 30 Boeing 737 MAX Jets to Expand Single-Aisle Fleet — Neutral

BA   PRNewsWire — January 29, 2026

- Purchase includes 20 737-8 and 10 737-10 airplanes for domestic, regional growth- Additional 737 MAX jets support strong single-aisle demand in one of the world's fastest-growing aviation markets HYDERABAD, India, Jan. 29, 2026 /PRNewswire/ -- Boeing [NYSE: BA] and Air India announced today the airline has ordered 30 more fuel-efficient 737 MAX jets, expanding its Boeing order book to nearly 200 airplanes across the company's single-aisle and widebody airplane families. The airline finalized an incremental purchase of 20 737-8 jets this month and an order for 10 737-10 airplanes was previously unidentified on Boeing's Orders & Deliveries website.

image for news Air India Orders 30 Boeing 737 MAX Jets to Expand Single-Aisle Fleet

Sibanye Stillwater: More Gains To Come — Positive

SBSW   Seeking Alpha — January 29, 2026

Sibanye Stillwater Ltd. (SBSW) has rebounded sharply, tripling adjusted EBITDA in Q3 as gold and PGM prices surged. SBSW's US PGM operations returned to profitability; cost management should improve with Sandouville's transition and new energy projects. Dividend resumption (25–35% of normalized earnings) is plausible by late 2026, supporting further upside after a 500%+ YoY rally.

image for news Sibanye Stillwater: More Gains To Come

Travere Therapeutics (TVTX) is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is intensifying, making FILSPARI's FSGS approval pivotal for the company's future growth. FILSPARI's FSGS indication represents a $2 billion U.S. peak sales opportunity, with no current FDA-approved therapies for this disease.

image for news Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think

Nasdaq Beats Q4 Earnings & Revenue Estimates, Tweaks Expense View — Positive

NDAQ   Zacks Investment Research — January 29, 2026

NDAQ's fourth-quarter results reflect higher revenues across divisions and organic growth, partially offset by higher expenses.

image for news Nasdaq Beats Q4 Earnings & Revenue Estimates, Tweaks Expense View

Lockheed Martin shares jump as defense buildup outlook overshadows mixed earnings — Positive

LMT   Proactive Investors — January 29, 2026

Lockheed Martin Corp (NYSE:LMT) shares jumped more than 5% on Thursday after the US defense contractor posted mixed quarterly results but pointed to a swelling order backlog and a major ramp-up in missile production that investors see as driving growth in the years ahead. The company reported fourth-quarter earnings per share of $5.80, while revenue rose 9.1% from a year earlier to $20.3 billion, helped by record deliveries of its F-35 fighter jet.

image for news Lockheed Martin shares jump as defense buildup outlook overshadows mixed earnings

The National Highway Traffic Safety Administration said that the child ran across the street from behind a double-parked SUV before being struck by the autonomous vehicle, sustaining minor injuries.

image for news Waymo Robotaxi Hits Child Near Elementary School, Prompting NHTSA Investigation

Cimpress plc (CMPR) Q2 2026 Earnings Call Transcript — Neutral

CMPR   Seeking Alpha — January 29, 2026

Cimpress plc (CMPR) Q2 2026 Earnings Call Transcript

image for news Cimpress plc (CMPR) Q2 2026 Earnings Call Transcript

Philadelphia, Pennsylvania--(Newsfile Corp. - January 29, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against SLM Corporation a/k/a Sallie Mae (NASDAQ: SLM) ("Sallie Mae" or the "Company") on behalf of investors who purchased or otherwise acquired Sallie Mae securities during the period of July 25, 2025 through August 14, 2025 (the "Class Period"), inclusive. Investor Deadline: Investors who purchased Sallie Mae securities during the Class Period may, no later than February 17, 2026, seek to be appointed as a lead plaintiff representative of the class.

image for news SLM CORPORATION A/K/A SALLIE MAE (SLM) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action

Rare-earth mining stocks slid after a report suggested the U.S. may rethink price-floor support—but analysts say government backing remains intact.

image for news MP, Rare Earth Stocks Sink on Price-Floor Fears. This Could Be a Buying Opportunity.

Sherwin-Williams' Q4 Earnings and Revenues Surpass Estimates — Positive

SHW   Zacks Investment Research — January 29, 2026

SHW tops Q4 estimates as revenues rise 5.6% Y/Y, with strength in Consumer Brands and Performance Coatings and an upbeat 2026 outlook.

image for news Sherwin-Williams' Q4 Earnings and Revenues Surpass Estimates

CHARLESTOWN, Ind., Jan. 29, 2026 /PRNewswire/ -- Indiana American Water held a ribbon cutting ceremony today at its Charlestown water treatment plant.

image for news Indiana American Water Installs First Drinking Water PFAS Treatment System in Indiana

Hercules Capital: 7 Reasons Why This Is The Top BDC For 2026 — Positive

HTGC   Seeking Alpha — January 29, 2026

I'm maintaining a "Buy" rating on Hercules Capital as I believe there are seven key reasons why it remains the top pick in the BDC sector for 2026. HTGC's business model is well adapted to the rate-cutting cycle, demonstrating effective scaling through its internal management structure and a clear commitment to diversifying cash flows. HTGC's dividend yield is expected to remain stable, while technical analysis of higher timeframes indicates further upside potential for the stock.

image for news Hercules Capital: 7 Reasons Why This Is The Top BDC For 2026

Can Allstate Beat Q4 Earnings on Property-Liability Strength? — Positive

ALL   Zacks Investment Research — January 29, 2026

ALL heads into Q4 earnings with expectations for strong property-liability underwriting gains and higher premiums that could drive another earnings beat.

image for news Can Allstate Beat Q4 Earnings on Property-Liability Strength?

Will Origination & Servicing Strains Drag Rithm Capital's Q4 Earnings? — Negative

RITM   Zacks Investment Research — January 29, 2026

RITM heads into Q4 with shaky servicing revenue, putting pressure on earnings despite strength in asset management.

image for news Will Origination & Servicing Strains Drag Rithm Capital's Q4 Earnings?